The Clusterin (CLU) ELISA Kit market encompasses immunoassay kits used to quantify the glycoprotein clusterin in biological samples, a critical biomarker for neurodegenerative disorders, cancer progression, and inflammatory diseases. This market overview provides an executive‑ready snapshot of the Clusterin (CLU) ELISA Kit market size, growth outlook, market forecast, and industry expansion across research, clinical, and pharmaceutical segments. In 2025 the market is estimated at approximately $10 million, driven by rising R&D investments in Alzheimer’s disease and oncology, alongside expanding biobanking activities. The forecast projects a compound annual growth rate (CAGR) of ~9% through 2033, propelled by advances in high‑sensitivity assay technologies, increased funding for biomarker discovery, and supportive regulatory pathways for diagnostic kit validation. Key forces shaping the industry include rapid technology shifts toward multiplex platforms, tightening regulatory standards for clinical-grade reagents, and intensified competition among major life‑science vendors. North America remains the largest market, while Asia‑Pacific is emerging as the fastest‑growing region, reflecting heightened research funding and expanding biotech ecosystems.
